Encenicline
From Wikipedia, the free encyclopedia
(Redirected from EVP-6124)
Jump to: navigation, search
 |
|
| Systematic (IUPAC) name | |
|---|---|
|
N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-7-chloro-1-benzothiophene-2-carboxamide
|
|
| Identifiers | |
| CAS Number | 550999-75-2 |
| ATC code | None |
| PubChem | CID 46196517 |
| ChemSpider | 28637768 |
| ChEMBL | CHEMBL2151572 |
| Chemical data | |
| Formula | C16H17ClN2OS |
| Molar mass | 320.837 g/mol |
|
|
|
|
Encenicline (INN, USAN) (code names EVP-6124, MT-4666) is a selective partial agonist of the α7 nicotinic receptor, and is in phase III clinical trials for the treatment of cognitive impairment in schizophrenia.[1][2]
See also[edit]
References[edit]
- ^ Melville, Nancy A. "Novel Drug Targets 'Huge Unmet Need' in Schizophrenia". Medscape. Retrieved 13 April 2015.
- ^ Barbier, AJ (2015-02-01). "Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Encenicline, a Selective α7 Nicotinic Receptor Partial Agonist, in Single Ascending-dose and Bioavailability Studies". Clinical Therapeutics. 37 (2): 311–24. doi:10.1016/j.clinthera.2014.09.013. PMID 25438724.
External links[edit]
| AChE inhibitors | |
|---|---|
| Others | |
 |
This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |
